<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04713254</url>
  </required_header>
  <id_info>
    <org_study_id>19353A</org_study_id>
    <nct_id>NCT04713254</nct_id>
  </id_info>
  <brief_title>Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men</brief_title>
  <official_title>Interventional, Open-label, One-sequence Study to Investigate the Effects of Lu AG06466 on the Pharmacokinetics of the Cytochrome P450 Substrates Midazolam (CYP3A4), Bupropion (CYP2B6), and Metoprolol (CYP2D6) in Healthy Young Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of repeated doses of the drug Lu AG06466&#xD;
      on the exposure of metoprolol, midazolam and bupropion&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On Day 1, midazolam and metoprolol will be dosed as an oral single-dose cocktail and PK&#xD;
      sampling will be performed for 48 hours.&#xD;
&#xD;
      On Day 3, bupropion will be dosed as a single oral dose and PK sampling will be performed for&#xD;
      48 hours.&#xD;
&#xD;
      On Days 5-18, subjects will be dosed with Lu AG06466 once daily.&#xD;
&#xD;
      On Day 15, midazolam and metoprolol will be dosed as an oral single-dose cocktail and PK&#xD;
      sampling will be performed for 48 hours.&#xD;
&#xD;
      On Day 17, bupropion will be dosed as a single oral dose and PK sampling will be performed&#xD;
      for 48 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Actual">April 9, 2021</completion_date>
  <primary_completion_date type="Actual">April 9, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC 0-inf for midazolam</measure>
    <time_frame>Day 1 and Day 15</time_frame>
    <description>Area under the midazolam plasma concentration-time curve from zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-inf for metoprolol</measure>
    <time_frame>Day 1 and Day 15</time_frame>
    <description>Area under the metoprolol plasma concentration-time curve from zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-inf for bupropion</measure>
    <time_frame>Day 3 and Day 17</time_frame>
    <description>Area under the bupropion plasma concentration-time curve from zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for midazolam</measure>
    <time_frame>Day 1 and Day 15</time_frame>
    <description>Maximum observed plasma concentration for midazolam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for metoprolol</measure>
    <time_frame>Day 1 and Day 15</time_frame>
    <description>Maximum observed plasma concentration for metoprolol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for bupropion</measure>
    <time_frame>Day 3 and Day 17</time_frame>
    <description>Maximum observed plasma concentration for bupropion</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lu AG06466</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AG06466</intervention_name>
    <description>10, 20, 30 mg/day oral capsules on Day 5-18</description>
    <arm_group_label>Lu AG06466</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>4 mg syrup, oral single dose on Day 1 and Day 15</description>
    <arm_group_label>Lu AG06466</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>100 mg tablets, oral single dose on Day 1 and Day 15</description>
    <arm_group_label>Lu AG06466</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>100 mg tablets, oral single dose on Day 3 and Day 17</description>
    <arm_group_label>Lu AG06466</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) of 18.5 to 30 kg/m2 (inclusive) at the Screening and Baseline&#xD;
             Visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has any concurrent disorder that may affect the pharmacological target or&#xD;
             absorption, distribution, or elimination of the investigational medicinal product.&#xD;
&#xD;
        Other in- and exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Dallas CRU</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

